Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1

Conditions

Ovarian Neoplasms 17Fallopian Tube Neoplasms 17Glioblastoma 7Colorectal Neoplasms 7Carcinoma, Non-Small-Cell Lung 7Lung Neoplasms 6Carcinoma, Renal Cell 6Brenner Tumor 6Melanoma 5Uterine Cervical Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Gliosarcoma 4Breast Neoplasms 4Brain Neoplasms 4Triple Negative Breast Neoplasms 3Recurrent Squamous Cell Lung Carcinoma 3Oligodendroglioma 3Neoplasm Metastasis 3Lymphoma, Large B-Cell, Diffuse 3Colonic Neoplasms 3Uveal Melanoma 2Spinal Cord Neoplasms 2Rectal Neoplasms 2Prostatic Neoplasms 2Medulloblastoma 2Glioma 2Endometrial Adenocarcinoma 2Carcinoma 2Astrocytoma 2Adenocarcinoma of Lung 2

Interventions

olaparib 1liposomal doxorubicin 1durvalumab 1cediranib 1Topotecan 1Taxes 1Specimen Handling 1Paclitaxel 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1Doxorubicin 1Disulfides 1Contrast Media 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Fallopian Tube Mucinous Adenocarcinoma × Disulfides × Clear all
NCT04739800 2026-05-29

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

National Cancer Institute (NCI)

Phase 2 Active not recruiting
120 enrolled 19 charts
GenitourinaryGynecologic

Fallopian Tube Mucinous Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡